Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0F5MA
|
|||
| Former ID |
DNC009246
|
|||
| Drug Name |
2,7-Bis(4-chlorobutyramido)anthraquinone
|
|||
| Synonyms |
2,7-Bis(4-chlorobutyramido)anthraquinone; SCHEMBL4293006
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C22H20Cl2N2O4
|
|||
| Canonical SMILES |
C1=CC2=C(C=C1NC(=O)CCCCl)C(=O)C3=C(C2=O)C=CC(=C3)NC(=O)CCCCl
|
|||
| InChI |
1S/C22H20Cl2N2O4/c23-9-1-3-19(27)25-13-5-7-15-17(11-13)22(30)18-12-14(6-8-16(18)21(15)29)26-20(28)4-2-10-24/h5-8,11-12H,1-4,9-10H2,(H,25,27)(H,26,28)
|
|||
| InChIKey |
OWZXQHSZHVLBPE-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | TERT messenger RNA (TERT mRNA) | Target Info | Inhibitor | [1] |
| KEGG Pathway | HTLV-I infection | |||
| NetPath Pathway | IL2 Signaling Pathway | |||
| Pathway Interaction Database | Validated targets of C-MYC transcriptional activation | |||
| Regulation of Telomerase | ||||
| IL2 signaling events mediated by PI3K | ||||
| Regulation of nuclear beta catenin signaling and target gene transcription | ||||
| HIF-1-alpha transcription factor network | ||||
| Reactome | Formation of the beta-catenin:TCF transactivating complex | |||
| WikiPathways | TGF beta Signaling Pathway | |||
| miR-targeted genes in lymphocytes - TarBase | ||||
| miR-targeted genes in epithelium - TarBase | ||||
| Telomere Maintenance | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Synthesis, human telomerase inhibition and anti-proliferative studies of a series of 2,7-bis-substituted amido-anthraquinone derivatives. Bioorg Med Chem. 2008 Jul 15;16(14):6976-86. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.